Brief: Xilio Therapeutics Reports Pipeline And Business Progress And Third Quarter 2021 Financial Results
02/12/2021 12:54
Dec 2 (Reuters) - Xilio Therapeutics Inc XLO.O :
* XILIO THERAPEUTICS REPORTS PIPELINE AND BUSINESS PROGRESS
AND
THIRD QUARTER 2021 FINANCIAL RESULTS
* XILIO THERAPEUTICS INC - ANTICIPATE FIRST PATIENT DOSING
IN
PHASE 1/2 CLINICAL TRIAL FOR XTX202, A TUMOR-SELECTIVE IL-2, IN
Q1 OF 2022
* XILIO THERAPEUTICS INC- SUBMISSION OF AN IND FOR XTX301 IN
SECOND HALF OF 2022
* XILIO THERAPEUTICS INC - EXISTING CASH, CASH EQUIVALENTS,
IPO
PROCEEDS WILL ENABLE CO TO FUND OPERATING EXPENSES AND CAPITAL
EXPENDITURE INTO 2024
* XILIO THERAPEUTICS INC - QTRLY NET LOSS PER SHARE $21.27
Source text for Eikon: ID:nGNXbLtXlT
Further company coverage: XLO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xilio Therapeutics
See all newsXilio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Xilio Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates
U.S. STOCKS ON THE MOVE-Palantir, AeroVironment, Valvoline
U.S. STOCKS ON THE MOVE-Medtronic, AeroVironment, Tesla